Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440372 · ClinicalTrials.gov registry record · Phase 3
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
A Phase 3 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 3
- Development phase
- 625
- Enrollment target
NCT03440372 is a Phase 3 study that was terminated before completion, run by Celgene. The registered enrollment target is 625 participants.
The verdict
NCT03440372, a Phase 3 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 625 participants
- Enrollment target
Study Summary
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Interventions
- OTHER Placebo
- DRUG Ozanimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 625 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03440372
The ClinicalTrials.gov registry entry for NCT03440372 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 625 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03440372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03440372 about?
NCT03440372 is a clinical study titled "Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease". This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
What is the current status of trial NCT03440372?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 625 participants. The study started on 2018-02-27. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT03440372?
The interventions under investigation include: Placebo (OTHER), Ozanimod (DRUG).
Who is sponsoring clinical trial NCT03440372?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.